- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT05423847
Triage UltraSound in Tb Endemic Regions (TrUST)
Point-of-care Ultrasound for the Diagnosis and Risk Stratification of Lower Respiratory Tract Infections in TB Endemic Regions: a Multicenter Prospective Cohort Study
A tanulmány áttekintése
Állapot
Körülmények
Beavatkozás / kezelés
Részletes leírás
Design International multicentre prospective cohort study
Setting This study aims to explore the performance of POCUS in a pre-hospital setting in countries with different prevalences of HIV: South- Africa (high prevalence), Benin (low prevalence) and Mali (low prevalence).
Study procedures Pre-recruitment training Before initiating the study, participating clinicians will benefit from lung ultrasound (LUS) and POCUS protocols for extra pulmonary TB (FASH+ exam) training with a field expert. The participating clinicians are required to pass a final expert test before start of patient recruitment and to have a minimum of 20 supervised US.
Inclusion (Day 0) Patients inclusion will be performed over a period of 18 to maximum 24 months. Recruitment will stop before the anticipated end if the inclusion of 1000 patients is reached.
Clinical data Data collected include demographic characteristics (age, sex, occupation etc.), past medical history (previous TB, Coronavirus Disease (COVID), vaccination status, documented past episodes of COVID-19, HIV status,…), symptoms (respiratory symptoms, specific COVID-19 symptoms (from the Centers for Disease Control COVID checklist), specific pulmonary TB symptoms (from the CDC TB checklist) and routine clinical examination findings (vital parameters, oxygen saturation, lung auscultation,…).
Laboratory analyses
Analyses performed on site:
- HIV screening with a serial two rapid test algorithm as per World Health Organization (WHO) guidelines : Screening with Alere Determine combo®; if positive, confirmation by a second rapid test First Response® HIV 1-2-0, CD4 count and/or Viral load as per national guidelines.
- Sputum for GeneXpert Mycobacterium Tuberculosis (MTB)/rifampicine (RIF) assay
- Induced sputum for a new GeneXpert MTB assay if a routine spot and second morning GeneXpert MTB is negative and sputum quality was low (salivary) as per WHO consolidated guidelines
- Sputum for Gram stain and standard bacteriological culture
- Nasopharyngeal swab for Severe Acute Respiratory Syndrome Coronovirus (SARS-CoV-2) real-time polymerase chain reaction (RT-PCR) (Cepheid Xpert Xpress SARS-CoV-2) Since the additional diagnostic yield of mycobacterial culture is shown to be very low in adult patients with cough in Benin, it is reserved for GenXpert MTB/RIF resistant cases, specimens other than sputum (e.g. pleural effusions, where sensitivity of GeneXpert MTB/RIF is low) and patients with treatment failure. Mycobacterial culture will be done on solid medium (Löwenstein-Jensen).
Analyses performed retrospectively on stored samples:
- Nasopharyngeal swab: PCR for influenza
- Sputum: syndromic molecular panel targeting influenza and atypical bacteria. Radiological examinations
- Chest X-Ray (CXR) - face: digital format will be stored
- LUS exam using a standard point-of-care ultrasound device (ultrasound-on-a-chip), LUS will be recorded according to a standard 12-point acquisition protocol with 4 additional apical sites (2 subclavicular and 2 axillary) for improved TB detection.
- This involves scanning both apexes, the anterior and posterior apexes, anterior superior, anterior inferior, posterior superior, posterior inferior and lateral thorax regions
- FASH plus exam using a standard point-of-care ultrasound device. The FASH plus protocol will be performed in a standardized manner as previously described.
All US images captured will be digitally recorded and transferred via a secured internet connection along with relevant metadata to a secure server for storage. For study quality control purposes, the quality of the image and the interpretation of a random sample of images will be evaluated retrospectively by an experienced radiologist.
Clinician-evaluated LUS and FASH All LUS and FASH exams will be read by 2 independent readers blinded to patients diagnosis and outcome. A third reader will solve discrepancies between the two readers. They will fill in a standardized LUS and FASH report.
AI-evaluated LUS and FASH The US images will be further used for secondary studies developing deep learning algorithms for LUS and FASH diagnosis.
Follow-up (D7 and D28) Patients will receive a follow-up phone call by the study nurse on day 7 and day 28. Data on the clinical evolution are collected: hospitalization, non-invasive ventilation, intubation, death.
Follow-up of TB treatment failures and deaths until D180 TB patients will be followed in the national TB register and treatment failures will be recorded at 6 months of treatment (according to national guidelines).
Deaths will be recorded until D180 as well.
Tanulmány típusa
Beiratkozás (Várható)
Kapcsolatok és helyek
Tanulmányi kapcsolat
- Név: Noémie Boillat-Blanco, MD-PhD, PD
- Telefonszám: +41 (0)79 556 16 86
- E-mail: noemie.boillat@chuv.ch
Tanulmányozza a kapcsolattartók biztonsági mentését
- Név: Veronique Suttels, MD
- Telefonszám: +229 97 44 87 82
- E-mail: veronique.suttels@outlook.com
Tanulmányi helyek
-
-
Atlantic
-
Cotonou, Atlantic, Benin
- Toborzás
- CNHUPPC
-
Kapcsolatba lépni:
- Gildas Agodokpessi, Prof
- E-mail: aggildas@yahoo.fr
-
-
-
-
-
Acornhoek, Dél-Afrika
- Toborzás
- Wits Rural University
-
Kapcsolatba lépni:
- Jacques Du Toit
- E-mail: jacques.dutoit1@wits.ac.za
-
-
-
-
-
Bamako, Mali
- Még nincs toborzás
- CHU point G
-
Kapcsolatba lépni:
- Khadidia Ouattara, MD
- E-mail: zankhadi@gmail.com
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Mintavételi módszer
Tanulmányi populáció
- Benin: 6'500 cumulative total detected and declared COVID-19 cases since march 2020 to date (NB true COVID-19 incidence unknown due to undertesting), TB incidence 55/100'000/year, low HIV (prevalence < 2%)
- South Africa: 1,522'697 cumulative total detected and declared COVID-19 cases since march 2020 to date TB incidence 615/100.000/year, high HIV (prevalence approximately 20%)
- Mali: 30'420 cumulative total detected and declared COVID-19 cases since march 2020 to date (NB true COVID-19 incidence unknown due to undertesting), TB incidence 52/100'000/year, low HIV (prevalence < 2%)
Leírás
Inclusion Criteria:
- Age ≥18 years
- Suspicion of lower respiratory tract infection (defined as presence of cough with at least one of the following: fever, dyspnea/tachypnea, sputum production, chest pain, hemoptysis or cachexia)
Exclusion Criteria:
- Cough/dyspnea from a definite non-infectious origin (cardiac, asthmatic...)
- Inability to cooperate with ultrasound procedure
- Inability to sign informed consent (third witness procedure available for illiterate patients)
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
Kohorszok és beavatkozások
Csoport / Kohorsz |
Beavatkozás / kezelés |
---|---|
Benin1
Benin urban recruitment site National teaching hospital for tuberculosis, outpatient emergency department
|
POCUS of lungs, pericardium and abdomen
|
Mali1
Mali urban recruitment site University Hospital Bamako, outpatient emergency department
|
POCUS of lungs, pericardium and abdomen
|
South-Africa1
South-Africa rural recruitment site 1 Tintswalo hospital, outpatient emergency department
|
POCUS of lungs, pericardium and abdomen
|
South-Africa2
South-Africa rural recruitment site 2 Zithulele hospital, outpatient emergency department
|
POCUS of lungs, pericardium and abdomen
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
---|---|---|
Sensitivity of LUS for the detection of TB
Időkeret: 18 to 24 months
|
For LUS, each lung quadrant will be scored using a 6 feature LUS score (modified Soldati score) ranging from 1 (aerated lung), 2 (interstitial syndrome), 3 (sub centimeter pleural lesions), 4 (lung consolidation), 5 (pleural effusion) to 6 (pneumothorax).
Sensitivity of LUS score for the diagnosis of TB using microbiological tests (GenXpert MTB/RIF for HIV negative patients, mycobacterial culture for HIV patients and extra-pulmonary samples) as reference standards
|
18 to 24 months
|
Specificity of LUS for the detection of TB
Időkeret: 18 to 24 months
|
For LUS, each lung quadrant will be scored using a 6 feature LUS score (modified Soldati score) ranging from 1 (aerated lung), 2 (interstitial syndrome), 3 (sub centimeter pleural lesions), 4 (lung consolidation), 5 (pleural effusion) to 6 (pneumothorax).
Sensitivity of LUS score for the diagnosis of TB using microbiological tests (GenXpert MTB/RIF for HIV negative patients, mycobacterial culture for HIV patients and extra-pulmonary samples) as reference standards
|
18 to 24 months
|
Sensitivity of FASH PLUS for the detection of TB
Időkeret: 24 to 36 months
|
For the pericardial and abdominal ultrasound, a score according to the FASH PLUS protocol will be attributed ranging from 0 (no pathology) to 6 (presence of pericardial effusion, abdominal adenopathies, pleural effusion, splenic lesions, hepatic lesions, ascites).
Sensitivity of FASH PLUS score for the diagnosis of TB using microbiological tests (GenXpert MTB/RIF for HIV negative patients, mycobacterial culture for HIV patients and extra-pulmonary samples) as reference standards.
|
24 to 36 months
|
Specificity of FASH PLUS for the detection of TB
Időkeret: 24 to 36 months
|
For the pericardial and abdominal ultrasound, a score according to the FASH PLUS protocol will be attributed ranging from 0 (no pathology) to 6 (presence of pericardial effusion, abdominal adenopathies, pleural effusion, splenic lesions, hepatic lesions, ascites).
Specificity of FASH PLUS score for the diagnosis of TB using microbiological tests (GenXpert MTB/RIF for HIV negative patients, mycobacterial culture for HIV patients and extra-pulmonary samples) as reference standards.
|
24 to 36 months
|
Sensitivity of combined LUS and FASH PLUS features for the detection of TB
Időkeret: 24 to 36 months
|
Sensitivity of combined LUS and FASH PLUS score for the diagnosis of TB using microbiological tests (GenXpert MTB/RIF for HIV negative patients, mycobacterial culture for HIV patients and extra-pulmonary samples) as reference standards.
|
24 to 36 months
|
Specificity of combined LUS and FASH PLUS features for the detection of TB
Időkeret: 24 to 36 months
|
Specificity of combined LUS and FASH PLUS score for the diagnosis of TB using microbiological tests (GenXpert MTB/RIF for HIV negative patients, mycobacterial culture for HIV patients and extra-pulmonary samples) as reference standards.
|
24 to 36 months
|
Sensitivity of AI-interpreted LUS for the detection of TB
Időkeret: 24 to 36 months
|
LUS images will be scored binary by microbiological-label trained algorithms as TB or not TB.
Prediction: Sensitivity of AI-assisted interpretation LUS for the detection of TB using microbiological tests as reference standards
|
24 to 36 months
|
Specificity of AI-interpreted LUS for the detection of TB
Időkeret: 24 to 36 months
|
LUS images will be scored binary by microbiological-label trained algorithms as TB or not TB.
Prediction: Specificity of AI-assisted interpretation LUS for the detection of TB using microbiological tests as reference standards
|
24 to 36 months
|
Sensitivity of AI-interpreted FASH PLUS for the detection of TB
Időkeret: 24 to 36 months
|
FASH PLUS images will be scored binary by microbiological-label trained algorithms as TB or not TB.
Prediction: Sensitivity of FASH PLUS for the detection of TB using microbiological tests as reference standards
|
24 to 36 months
|
Specificity of AI-interpreted FASH PLUS for the detection of TB
Időkeret: 24 to 36 months
|
FASH PLUS images will be scored binary by microbiological-label trained algorithms as TB or not TB.
Prediction: Specificity of FASH PLUS for the detection of TB using microbiological tests as reference standards
|
24 to 36 months
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
---|---|---|
Qualitative assessment using semi-structured interviews (based on grounded theory methods) with end users of the barriers and facilitators of the implementation of POCUS
Időkeret: 12 months
|
Qualitative assessment using semi-structured interviews (based on grounded theory methods) with end users of the barriers and facilitators of the implementation of POCUS to assess its feasibility, sustainability and acceptability
|
12 months
|
Qualitative assessment using semi-structured interviews (based on grounded theory methods) with end users of the barriers and facilitators of the implementation of AI clinical decision support
Időkeret: 12 months
|
Qualitative assessment using semi-structured interviews (based on grounded theory methods) with end users of the barriers and facilitators of the implementation of AI clinical decision support to assess its feasibility, sustainability and acceptability
|
12 months
|
Együttműködők és nyomozók
Együttműködők
Nyomozók
- Kutatásvezető: Mary-Anne Hartley, MD-PhD, Ecole Polytechnique Fédérale de Lausanne
- Kutatásvezető: Noémie Boillat Blanco, MD-PhD, Lausanne University hospital
- Kutatásvezető: Veronique Suttels, MD, Lausanne University hospital
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
Elsődleges befejezés (Várható)
A tanulmány befejezése (Várható)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- CGRB11362
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
az Egyesült Államokban gyártott és onnan exportált termék
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .
Klinikai vizsgálatok a POCUS
-
Youngstown State UniversityToborzásPatellofemoralis rendellenességEgyesült Államok
-
Randa Ahmed SarhanMég nincs toborzásLégszomj | Krónikus veseelégtelenség
-
University of MinnesotaBefejezveKoronavírus fertőzés | Covid-19 | COVID | SARS-CoV-2Egyesült Államok
-
Sheba Medical CenterToborzásSzív-és érrendszeri betegségek | Szívbillentyű-betegségIzrael
-
Alexandria UniversityMég nincs toborzás
-
St. Justine's HospitalBefejezve
-
Cliniques universitaires Saint-Luc- Université...Grand Hôpital de Charleroi; Université de Liège; Clinique Saint-Jean, Bruxelles; Clinique...Még nincs toborzásPoCUS diagnosztikai pontosság széklethatás esetén a sürgősségi osztályon: jövőbeli tanulmány (FICUS)A vastagbél széklet hatása
-
Chinese University of Hong KongGormin Tan gtanJelentkezés meghívóval
-
FlevoziekenhuisToborzás
-
Western University, CanadaBefejezve